Related Experiment Video
Updated: Jun 21, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Chemoradiotherapy in gastrointestinal malignancies.
1Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. christopher.willett@duke.edu
Clinical Oncology (Royal College of Radiologists (Great Britain))
|July 7, 2009
Summary
Chemoradiotherapy improves outcomes for gastrointestinal cancers like esophageal and rectal. Definitive or neoadjuvant chemoradiotherapy shows promise, but its role in pancreatic cancer requires further research.
Area of Science:
- Oncology
- Gastroenterology
- Radiation Oncology
Background:
- Significant advances in integrating radiation therapy and chemotherapy for gastrointestinal malignancies over 30 years.
- Chemoradiotherapy aims to improve local control, survival, and outcomes for patients.
Purpose of the Study:
- To review randomized studies defining optimal sequencing, agents, and efficacy of chemoradiotherapy in gastrointestinal cancers.
- To highlight current results, controversies, and future directions in chemoradiotherapeutic treatment.
Main Methods:
- Review of randomized clinical trials and studies in esophageal, stomach, pancreatic, colon, rectal, and anal cancers.
- Analysis of treatment outcomes, including survival rates, local control, and morbidity.
Main Results:
- In esophageal cancer, definitive chemoradiotherapy offers survival comparable to neoadjuvant chemoradiotherapy followed by surgery.
- Neoadjuvant chemoradiotherapy in locally advanced rectal cancer improves local control and reduces morbidity compared to adjuvant therapy.
- The efficacy of chemoradiotherapy in pancreatic cancer remains uncertain and debated.
Conclusions:
- Chemoradiotherapy is a valuable treatment modality for localized gastrointestinal malignancies, particularly esophageal and rectal cancers.
- Optimal treatment strategies and sequencing continue to evolve, with ongoing research needed for pancreatic cancer.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...